徐寒梅

徐寒梅,博士,中国药科大学教授(博士生导师),国家级人才项目入选者,海洋药学专业负责人,江苏省合成多肽药物发现与评价工程研究中心主任,国家药典委员会生物技术委员会委员。

    研究领域包括多肽药物研究与开发、全新微肽发现及机制研究、长链非编码RNA与疾病关系的分子机制、开关调控的双识别CAR-T细胞对实体瘤的治疗等。主编出版了3部学术论著,发表学术论文160篇,其中SCI收录66篇,包括发表在JACsCCRCellNature子刊的文章。先后获得多项奖励。

 

代表性著作:

1. 2020年 新药非临床研究与开发。主编:徐寒梅,中国医药科技出版社,出版号ISBN9787521419207

2. 2015年 抗肿瘤药物药理学实验指南。主编:徐寒梅,中国医药科技出版社,出版号ISBN9787506778220

3. 2011年 酶类药物学。副主编:徐寒梅,中国医药科技出版社,出版号ISBN9787506746960

 

代表性学术论文:

  1. Peiwei Yang, Ying Wang, Zheng Yao, Xinmei Gao, Chen Liu, Xinmin Wang, Heming Wu, Xu Ding, Jialiang Hu, Bingjing Lin, Qian Li, Mengwei Li, Xin Li, Xiangying Chen, Weiyan Qi, Weiguang Li, Jianpeng Xue,* and Hanmei Xu*. Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide. J Am Chem Soc. 2020 Nov 4;142(44):18874-18885. (IF=14.612)

    2. Mengwei Li, Xu Ding, Yinan Zhang, Xin Li, Haoze Zhou, Li Yang, Yilin Li, Peiwei Yang, Xiaomin Zhang, Jialiang Hu, Edouard Nice, Heming Wu*, Hanmei Xu*. Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin pathway in head and neck squamous cell carcinomas. Cell Death Dis. 2020 Aug 13;11(8):672.  (IF=6.304)

    3. Mengwei Li, Xin Li, Yinan Zhang, Heming Wu, Haoze Zhou, Xu Ding, Xiaomin Zhang, Xinrong Jin, Ying Wang, Xinqiang Yin, Chencheng Li, Peiwei Yang, Hanmei Xu*. Micropeptide MIAC Inhibits HNSCC Progression by Interacting with Aquaporin 2. J Am Chem Soc. 2020 Apr 8;142(14):6708-6716. (IF=14.612)

    4. Ying Wang, Jiqiang Lu, Lin Chen, Huan Bian, Jialiang Hu, Dongping Li, Chunlei Xia, Hanmei Xu*. Tumor-Derived EV-Encapsulated miR-181b-5p Induces Angiogenesis to Foster Tumorigenesis and Metastasis of ESCC. Mol Ther Nucleic Acids. 2020 Jun 5;20:421-437. (IF=7.032)

    5. Ying Wang, Dongping Li, Jiqiang Lu, Lin Chen, Shengnan Zhang, Weiyan Qi, Weiguang Li, Hanmei Xu*. Long noncoding RNA TTN-AS1 facilitates tumorigenesis and metastasis by maintaining TTN expression in skin cutaneous melanoma. Cell Death Dis. 2020 Aug 20;11(8):664.  (IF=6.304)

    6. Li Dongping, Wang Ying, Jin Xinrong, Hu Die, Xia Chunlei, Xu Hanmei*, Hu Jialiang*. NK cell-derived exosomes carry miR-207 and alleviate depression-like symptoms in mice.[J]. J Neuroinflammation, 2020, Apr 22, 17: 126 (IF=5.7)

    7. Zhang E, Yang P, Gu J, Wu H, Chi X, Liu C, Wang Y, Xue J, Qi, Sun Q, Zhang S, Hu J, Xu H*. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018, 11(1):102. (IF=11.059)

    8. Erhao Zhang, Jieyi Gu and Hanmei Xu*. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018, 17(1):7. (IF=15.302)

    9. Zhang E, Gu J, Xue J, Lin C, Liu C, Li M, Hao J, Setrerrahmane S, Chi X, Qi W, Hu J*, Xu H*. Accurate control of dual-receptor- engineered T cell activity through a bifunctional anti-angiogenic peptide. J Hematol Oncol. 2018 Mar 20;11(1):44. (IF=11.059)

    10. Setrerrahmane S, Xu H*. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017 Sep 19;16(1):153. (IF=15.302)

    11. Erhao Zhang, Hanmei Xu*. A new insight in chimeric antigen reeptor-engineered T cells for cancer immunotherapy. Journal of Hematology and Oncology, 2017,10:1-11. (IF=11.059)

     

    联系方式

    邮箱:13913925346@126.com